title: Presence of factor-VII and -XIII activity in ultrafiltrate during hemofiltration.
abstract: Bleeding complications during renal replacement therapies can be attributed to coagulation system and platelet function alterations in uremia, and the application of heparin in extracorporeal circulation. Small protein losses during hemofiltration are always described, however the high molecular weight of coagulation factors should significantly prevent their removal during hemofiltration. To exclude degradation of coagulation factors under conditions of spontaneous ultrafiltration, the hemofiltrate of 40 patients with acute renal failure (treated with continuous veno-venous hemofiltration, CVVH) was sampled from the filtrate line after 1 h from the beginning of treatment and in 5 patients also after 12 and 24 h. Samples were investigated with human factor deficient plasma (VII, X, XI, XII) from donors with a congenital deficiency and with human plasma depleted of factor V, VIII, IX, and protein S and C. Factor XIII was detected photometrically. Subsequently the presence of factor- XIII and -VII activity was investigated in plasma and hemofiltrate from 16 patients treated with intermittent hemofiltration before (plasma) and after (plasma, hemofiltrate) therapy. These patients also suffered from acute renal failure and needed renal replacement therapies. Quality control was carried out with a buffer solution (<1% activity in the assays according to recommended protocols).
  
  
  RESULTS
  Factor-V, -VIII, -IX, -X, -XI, and -XII activity, and protein C and S could not be detected in the hemofiltrate from continuous hemofiltration. Factor-VII and -XIII activity was present in the hemofiltrate (mean activity in CVVH: 1.93% for factor VII and 6.9% for factor XIII, mean activity in intermittent hemofiltration: <1% for factor-VII and 7.3% for factor-XIII). Three were no significant differences (Student's t-test) in plasma activity before and after intermittent hemofiltration of factor VII (44 vs. 47%, p = 0.39) and factor XIII (44 vs. 52%, p = 0.24). The presence of factor-VII and -XIII activity in the hemofiltrate cannot influence plasma activities in intermittent hemofiltration. Rapid new synthesis and short half-life should neutralize these effects. Elimination of coagulation factor-XIII activity should be excluded by the next generation of highly permeable membranes and on-line hemodiafiltration.
authors.affiliation: Department of Internal Medicine A, University of Greifswald, Germany.
authors.forename: H J
authors.initials: HJ
authors.lastname: Guth
authors.forename: A
authors.initials: A
authors.lastname: Klingbeil
authors.forename: I
authors.initials: I
authors.lastname: Wiedenhöft
authors.forename: H J
authors.initials: HJ
authors.lastname: Rose
authors.forename: G
authors.initials: G
authors.lastname: Kraatz
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000628:therapy; D000990:Antithrombin III / Q000032:analysis; D001780:Blood Coagulation Tests; D005167:Factor VII / Q000032:analysis*; D005176:Factor XIII / Q000032:analysis*; D006440:Hemofiltration; D006801:Humans
chemical_list: D000990:Antithrombin III; D005167:Factor VII; D005176:Factor XIII